News

Morbidities linger at least 20 years for young adult cancer survivors


 

References

Survivors of young adult cancers had 1.5 times more hospitalizations than did controls in a population-based study spanning 20 years, Dr. Devon P. Richardson and coauthors at the University of Toronto reported online in the Journal of Clinical Oncology.

Investigators compared a cohort of 20,275 patients enrolled in the Ontario Cancer Registry who were aged 20-44 years at the time of diagnosis, and had survived at least 5 years cancer free, with 101,344 noncancer controls selected from a roster of all individuals eligible for the Ontario Health Insurance Plan. Over one-third of survivors were hospitalized during the 20-year study period, and the adjusted relative rate (ARR) of hospitalizations, compared with controls, was 1.51 (95% confidence interval, 1.48-1.54). Hospitalization rates were highest in survivors of upper GI cancers (ARR, 2.49), leukemia (ARR, 2.23), and urologic (ARR, 2.20) cancers, the investigators reported.

In the first three follow-up periods (5-8, 9-11, and 12-14 years after diagnosis), the hospitalization rate in survivors (per 100 person-years) stayed constant at 0.22, whereas the rate decreased significantly in the last two time periods: 0.17 at 15-17 years and 0.15 for 18-20 years after diagnosis (P <.0001). The hospitalization rate among controls was relatively constant during the entire time period, ranging from 0.12 to 0.14, they said.

“The results of our study show that 5-year survivors of cancer diagnosed during young adulthood will have morbidities that increase the number of hospitalizations in this cohort compared with control subjects for at least 20 years after diagnosis,” the authors wrote.

Read the full article here: J. Clin. Oncol. 2015 July 13 (doi:10.1200/JCO.2014.60.1914).

Recommended Reading

Oncology hospitalist field is small, but growing
MDedge Pediatrics
NIH report on long-term opioid treatment cites lack of data, research needs
MDedge Pediatrics
Long-term endocrine effects common after reduced-intensity chemotherapy in children
MDedge Pediatrics
FDA strengthens allergy warning for IV anemia therapy ferumoxytol
MDedge Pediatrics
More children surviving cancer, but they still face chronic conditions
MDedge Pediatrics
Children with advanced cancer need greater palliative care
MDedge Pediatrics
PAS: Mind-body practices benefit teens with chronic illnesses
MDedge Pediatrics
VIDEO: Level of e-cigarette power contributes to potentially hazardous effects
MDedge Pediatrics
Less intensive childhood cancer therapy reduces late toxicities, deaths
MDedge Pediatrics
Hospital clinicians commonly work while sick
MDedge Pediatrics